Maintaining pancreatic b-cell mass and function is essential for normal insulin production and glucose homeostasis. Regenerating islet-derived 2 (Reg2, Reg II, human ortholog Reg1B) gene is normally expressed in pancreatic acinar cells and is significantly induced in response to diabetes, pancreatitis, and high-fat diet (HFD) and during pancreatic regeneration. To evaluate the role of endogenous Reg2 production in normal b-cell function, we characterized Reg2 gene-deficient (Reg2 2/2 ) mice under normal conditions and when subjected to several pathological challenges. At a young age, Reg2 gene deficiency caused no obvious change in normal islet morphology or glucose tolerance. There was no change in the severity of streptozotocin-induced diabetes or caeruleininduced acute pancreatitis in the Reg2 2/2 mice, indicating that the increased Reg2 expression under those conditions was not essential to protect the islet or acinar cells. However, 13-to 14-month-old Reg2 2/2 mice developed glucose intolerance associated with significantly decreased islet b-cell ratio and serum insulin level. Similarly, after young mice were fed an HFD for 19 weeks, diminished islet mass expansion and serum insulin level were observed in Reg2 2/2 vs wild-type mice. This was associated with a decline in the rate of individual b-cell proliferation measured by Ki67 labeling. In both conditions, the b-cells were smaller in gene-deficient vs wild-type mice. Our results indicate that normal expression of Reg2 gene is required for appropriate compensations in pancreatic islet proliferation and expansion in response to obesity and aging. (Endocrinology 158: 1634(Endocrinology 158: -1644(Endocrinology 158: , 2017 
T he increasing prevalence of obesity and its associated metabolic disorders, such as type 2 diabetes (T2D), has posed a great challenge for public health. T2D is characterized by defects in insulin production and responsiveness, and its prevalence increases substantially with age (1) . The pancreatic b-cell is the only source of insulin production in humans and most mammalian animals, and its growth potential determines the scope of insulin secretion. In obesity, b-cells exhibit excessive expansion to compensate for the increased demand of insulin and to maintain euglycemia (2, 3) . Insulin resistance and eventually T2D occur when islet compensation cannot be sustained. On the other hand, increased islet cell mass but decreased b-cell regeneration upon aging have been reported in rodents (4) . Obesity, aging, and b-cell malfunction are thus dynamically interconnected with the mechanism of insulin resistance and diabetes (5) . Maintaining a normal mass/function of b-cells and the sensitivity of peripheral organs to insulin is vital for controlling the onset of insulin resistance and diabetes.
The expression of Regenerating (Reg) proteins in pancreatic tissue is induced by islet hyperplasia, diabetes, or inflammatory stimuli. Among the seven members, Regenerating islet-derived 2 (Reg2, Reg II, human ortholog Reg1B) is normally expressed in pancreatic acinar cells in mice but is significantly induced in response to pancreatitis, high-fat diet (HFD), the treatment of exendin-4, and during regeneration after partial pancreatectomy (6) (7) (8) (9) (10) (11) (12) . We have demonstrated the induction of Reg2, Reg3a, and Reg3b genes in the pancreas by insulin-like growth factor 1 gene deficiency and streptozotocin-induced diabetes (13) . However, acinar overexpression of Reg2 gene did not offer protection to the islet cells in response to experimental diabetes induced by streptozotocin (14) . To further explore the normal physiological roles of Reg2 gene in regulating b-cell function and glucose homeostasis, we characterized a systemic gene deficiency in mice. This model is different from previously reported Reg3b gene deficiency, which was mislabeled as Reg2 (15, 16) . Although normal islet cell ratio and function were unaffected, Reg2 gene-deficient (Reg2
2/2
) mice displayed impaired islet compensations in response to aging and HFD-induced obesity.
Materials and Methods

Reg2
2/2 mice Reg2 2/2 mice were created by replacing the 2502-bp Reg2 gene (MGI: 97896) on chromosome 6 with a 6-kb ZEN-Ub1 cassette using homologous recombination and ES cell clone 10396E-H2 by the Knockout Mouse Project (UC Davis; www. komp.org). To achieve homozygosity, Reg2 +/2 heterozygous male and female pairs were intercrossed, and the offspring were weaned at 4 weeks of age. The animals were ear-tagged, and 0.5-cm tail sections were collected for DNA isolation and genotyping. Three polymerase chain reaction primers were used: Reg2GenoF (5 0 -TAT AGA ACC GTC GTT GGC AC), NeoF2 (5 0 -TGT GGT TTC CAA ATG TGT CAGT), and SD (5 0 -GAG AGA TAA AGA ATG CAT GGAG). The Reg2F/SD pair was used to amplify the endogenous Reg2 (628 bp), and NeoF/ SD was used to amplify the deleted allele (349 bp) [ Fig. 1(a) ]. Deletion of the Reg2 gene was further confirmed using Western blot and immunohistochemistry of the pancreas in 1-month-old mice. Mice had free access to water and food unless otherwise indicated for special treatments. All animal procedures were approved by the McGill University Animal Care Committee.
Streptozotocin-induced diabetes and caerulein-induced pancreatitis
Streptozotocin (75 mg/kg) was prepared freshly in 0.1 M sodium citrate (pH 4.5) and injected into 8-to 10-week-old Reg2 2/2 and wild-type (WT) littermates for 5 consecutive days. To monitor the onset of diabetes, body weight and blood glucose were recorded every 3 days for 12 days. For induction of pancreatitis, 6-to 8-week-old mice were fasted for 12 hours before being given 7-hourly injections of caerulein (50 mg/kg intraperitoneally) or vehicle. Mice were killed 11 hours after the injection, and pancreas and serum were collected for further analysis.
HFD feeding and aged mice
Homozygous Reg2
2/2 and WT littermates were fed HFD containing 60% fat (catalog no. D12492; Research Diets Inc.), starting from 2 to 3 months of age, for 19 weeks before being killed. For the aging study, Reg2 2/2 mice and age-matched WT mice were fed a chow diet until reaching 13 to 14 months of age. For glucose tolerance, mice were injected with 1 or 2 g/kg glucose intraperitoneally. Blood samples were taken from the tail vein and measured with a OneTouch Ultra glucose meter at 0, 15, 30, 60, and 120 minutes after the injection. For the insulin tolerance test, mice were injected with 0.75 U/kg insulin, and blood glucose was measured at 0, 20, 40, and 60 minutes after the injection. Changes in fat and lean masses were determined using an EcoMRI System. To reflect the extent of inflammation in adipose tissues, tholudine blue staining for mast cells was performed using the standard protocol. Insulin sensitivity index was calculated as 1/(log[Serum insulin] + log[Blood glucose]) (17) .
Tissue collection and serum insulin and amylase tests
At the end of each experiment, mice were killed with a cocktail injection of ketamine, xylazine, and acepromazine followed by cervical dislocation. Blood samples were collected, and supernatant serum was stored at 220°C until analysis. The pancreas and liver were removed; half was used to extract protein, and half was fixed in 10% formalin to prepare paraffin sections. Serum insulin level was measured by enzyme-linked immunosorbent assay following a standard protocol (ALPCO). Serum a-amylase level was tested using an enzymatic assay kit (Sigma).
Immunohistochemistry and immunofluorescence
Pancreatic sections (5 mm) were de-waxed and hydrated with graded ethanol. Sections were permeabilized with 0.1% Triton X-100, and endogenous peroxidase activity was blocked by 3% hydrogen peroxide. The sections were further blocked by 10% serum before being incubated with primary antibodies overnight at 4°C (Table 1) . Corresponding horseradish peroxidaseconjugated secondary antibodies were applied, followed by the incubation with DAB substrate (Vector Laboratories, Burlingame, CA). The slides were counterstained with hematoxylin to visualize the nucleus and mounted with hydrophobic mounting medium. Ki67 and caspase-3 immunohistochemistry was processed using a BenchMark Ultra Automated immunohistochemistry/in situ hybridization slide staining system (Ventana, Roche). For immunofluorescence, corresponding fluorescent antibodies were conjugated with Alexa 488 or Alexa 596. Primary antibodies used in this study include Reg2 (R&D Systems), insulin (Cell Signaling Technology), glucagon and Ki67 (catalog no. 790-4286; Ventana), and cleaved caspase-3 (catalog no. 9661S; Cell Signaling Technology). Histological images were captured using a Zeiss light and fluorescent microscope under 1003 and 4003 magnification. The pancreatic islet ratio was quantified by the areas of insulin-positive cells divided by the total tissue area using Image J software. Average b-cell size was calculated by the islet area divided by cell numbers of an individual islet. Quantification of Ki67-positive cells was performed by dividing the number of positive cells by total cell numbers in each islet. Each data set was created by selecting 5 to 8 representative images from each mouse.
Western blotting analysis
Pancreatic proteins were extracted using a lysis buffer (10 mM Tris, pH 7.5; 1 mM EDTA; 150 mM NaCl; 1% Triton X-100) containing protease inhibitor cocktail (Bioshop) and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were then transferred to a nitrocellulose membrane. Nonspecific bindings were blocked by 10% skim milk followed by incubation with primary antibodies at 4°C for overnight. Horseradish peroxidase-conjugated secondary antibodies were incubated for 1 hour followed by enhanced chemiluminescence substrates. The signals were captured using a ChemiDoc Touch Imaging System (Bio-Rad). Antibodies used include phospho-Akt at Ser-473 and total Akt (catalog no. 4058 and 9272), phospho-and total Erk1/2 (catalog no. 9101 and 9102; Cell Signaling Technology), Reg3a, Reg3b (R&D systems), and b-actin (MM-0164-P; Medimabs). Data were quantified using Image J and Image Laboratory (Bio-Rad).
Statistical analysis
All data are presented as means 6 SE. Data were analyzed by using Student t test, one-way analysis of variance, and two-way analysis of variance using GraphPad Prism version 6.0. Area under curve was calculated by using Prism. P , 0.05 was considered statistically significant.
Results
Reg2 gene deficiency did not alter glucose tolerance in young mice
To confirm the deletion of Reg2 gene, three primers were designed to amplify different fragments of the endogenous Reg2 gene or ZEN-Ub1 cassette by polymerase chain reaction [ Fig. 1(a) ]. The homozygous Reg2 2/2 mice showed a 349-bp band, whereas WT mice showed a 628-bp band, and heterozygous Reg2 +/2 mice had both 2/2 male mice. Reg2 was stained in peri-islet acinar cells, as reported (7). Glucagon was used to mark the islet. Images were taken at 3400 oil. Scale bar, 20 mm. PC, positive control of Reg2-rich pancreatic extract from acute pancreatitis.
[ Fig Using immunofluorescence, we observed Reg2 expression in exocrine pancreas of WT mice as previously reported (18) Reg2 deficiency did not affect streptozotocininduced diabetes and caerulein-induced acute pancreatitis Because Reg2 gene deficiency did not alter normal islet phenotype in young mice, we challenged the animals with streptozotocin or caerulein to test whether endogenous Reg2 production protects the islets from type 1 diabetes or the acini against pancreatitis. Multiple low-dose streptozotocin has been shown to mimic autoimmune insulitis and to produce insulindependent diabetes (i.e, type 1 diabetes) (20) . WT and Reg2 2/2 mice (8 to 9 weeks old) receiving vehicle did not exhibit any change in blood glucose and body weight (data not shown). After streptozotocin injections, blood glucose level reached above 400 mg/dL after 6 days and remained high in all animals until they were killed at 12 days [ Fig. 2(d) ]. No significant difference was observed in male or female Reg2 2/2 vs WT mice regarding body weight and blood glucose level.
As a cholecystokinin analog, hourly injections of a supermaximal doses of caerulein induce acute pancreatitis, characterized by hyperamylasemia, pancreatic edema, and acinar vacuolization (21) . In caeruleininjected WT mice, we observed an approximately fourfold increase in serum amylase level [ Fig. 2(e) ], significant neutrophil infiltration, and acinar cell death revealed using immunohistochemistry (data not shown) (14) . However, there was no difference between Reg2
and WT mice, indicating Reg2 deficiency did not affect streptozotocin-induced diabetes or caerulein-induced pancreatitis; the increased Reg2 expression under these conditions is not essential to protect the islet or acinar cells.
Reg2 gene deficiency impaired insulin production and glucose tolerance in aged mice Young mice may compensate for the lack of Reg2 expression better than old mice; aging is closely associated with increasing incidences of obesity and diabetes (22) . To explore the effect of aging, some Reg2 2/2 and WT mice were kept on chow diet for 13 to 14 months. At that age, Reg2 2/2 mice displayed a significant glucose intolerance vs WT littermates. Higher glucose levels were observed at 30, 60, and 120 minutes after glucose injection [ Fig. 3(a) ]. This was caused at least in part by decreased serum insulin level and islet cell ratio, indicating an essential role of endogenous Reg2 production in maintaining a normal islet mass/function in aged mice. We observed a smaller islet area using hematoxylin and eosin staining and immunohistochemistry for insulin in Reg2 2/2 vs WT mice [ Fig. 3(b) ]; the quantification of % islet area to total tissue showed a significant 60% decrease in Reg2 2/2 mice [ Fig. 3(c) ]. Because the rate of b-cell proliferation in aged mice can be neglected (no Ki67 labeling), at least part of the decrease can be attributed to a diminished b-cell size [ Fig. 3(d) ]. Consistent with the islet hypotrophy, serum insulin level was also decreased by more than 50% [ Fig. 3(e) ]. On the other hand, Reg2
mice exhibited a slightly improved insulin tolerance [ Fig. 3(f) ], further supporting that islet hypotrophy and diminished insulin production contribute to glucose intolerance in aged Reg2 2/2 mice. Because glucose intolerance may lead to or be caused by lipid disorders in liver Mice (8-to 9-week-old) were injected with multiple low doses of streptozotocin (75 mg/kg) for 5 days. Body weight and blood glucose were monitored at 0, 3, 6, 9, and 12 days (n = 8 to 10). (e) Caerulein-induced acute pancreatitis. Mice (6-to 8-week-old) were given 7-hourly injections of caerulein (50 mg/kg) to induce pancreatitis. Serum amylase level was measured at 11 h (n = 8 to 10). *P , 0.05 and **P , 0.01 vs WT untreated.
and fat tissues, we observed increased lipid deposition (steatosis) in the liver of aged Reg2 2/2 vs WT mice [ Fig. 3(g) ].
Aged Reg2 2/2 mice showed a 30% increase in percentage of fat mass and increased mast cell infiltration [ Fig. 3 (h) and 3(i)], a sign of increased inflammation, all of which may contribute to impaired glucose tolerance. There was no change in the overall body weight or in the weight of the pancreas (data not shown).
Reg2 gene deficiency protected mice from HFD-induced diabetes
Another challenge to Reg2 2/2 mice would be obesity-induced islet compensation. Because Reg2 gene expression is stimulated by diet-induced obesity and in pancreatic regeneration (10, 11), its deficiency was expected to be detrimental to obesity-induced islet expansion and the onset of diabetes. WT and Reg2 2/2 mice. Glucose (2 g/kg, intraperitoneally) was injected to mice at random fed. Area under the curve (AUC) was calculated for each curve by using GraphPad Prism. *P , 0.05 vs WT mice using 1-way analysis of variance (graphs) and t test (AUC), respectively (n = 6 to 8). The level of Reg2 gene expression in the pancreas has been known to be dependent on age, peaking at 30 days but vanishing after 90 days (7). Although our mice were 7 to 8 months of age by the end of the study, HFD and obesity are known to induce Reg2 reexpression (10) . Indeed, using caerulein-induced pancreatitis as a positive control [ Fig. 4(c) , upper panels], we detected patchy expression of Reg2 in the exocrine pancreas of WT mice after 19 weeks of HFD (middle panels), which was ablated by Reg2 gene deficiency (lower panels).
Diminished islet compensation to HFD caused by Reg2 gene deficiency
After the mice were killed, we studied islet histology and serum insulin. As shown in Fig. 5(a) (middle panels) , the compensation in islet area (indicating volume) to HFD in WT mice vs chow diet (left panels) was very obvious, especially regarding the size of the islets. However, Reg2
littermates showed very little islet expansion vs chow diet [ Fig. 4(a), right panels] ; the islet area was only 25% of that The compensation in islet cell number could be caused by increased cell proliferation or decreased cell death. Indeed, HFD caused a significant increase in islet cell proliferation, as indicated by Ki67 labeling in WT islets in the middle panels and column (from 0.95% to 6%), which was largely blunted by Reg2 gene deficiency in the right panels and column (1.7%) [ Fig. 5(e) and 5(f) ]. There was no significant change in the rate of cell apoptosis due to HFD as measured by the immunohistochemical staining of caspase-3 cleavage (data not shown). Although we did not measure insulin sensitivity directly during the HFD experiment, Reg2 2/2 mice demonstrated a significantly increased insulin sensitivity index [ Fig. 5(g) ]. This result supports the possibility that, in response to HFD and obesity, Reg2 gene deficiency caused islet hypotrophy and hypoplasia, supporting a normal stimulatory role provided by the endogenous gene expression.
Discussion
In this initial characterization of Reg2 gene deletion, we found no change in body weight, blood glucose level, and glucose tolerance in young adults. Despite the fact that Reg2 is normally expressed in acinar cells, Reg2 gene deficiency did not affect the severity of streptozototin-induced diabetes or caerulein-induced acute pancreatitis and its overexpression protected insulinoma cells in vitro (7, 25) . However, in aged mice, Reg2 deficiency caused diminished islet mass, decreased insulin level, and impaired glucose tolerance, which may be associated with hepatosteatosis, obesity, and adipose tissue inflammation. Similarly, in HFD-induced obesity, we demonstrated diminished compensations in the rate of islet cell proliferation, cell size, and % islet area and decreased serum insulin level, together with a seemingly increased insulin sensitivity may contribute to the protection of Reg2
mice from obesity-induced T2D. These findings prove that, under specific conditions, Reg2 expression is essential for islet maintenance and compensation. In rodents, Reg2 belongs to a family of seven members that are clustered in chromosome localization, expressed in overlapping tissue/cells, and share a high degree of sequence identities (26, 27) . Gene redundancy within this family may at least in part explain the lack of phenotype in normal islet growth and glucose homeostasis after the deletion of Reg2 gene alone. Moreover, it has been known that gene-deficient mice may not exhibit significant abnormality unless they are challenged with additional stresses (28) . Similarly, in streptozotocin-induced diabetes, not only Reg2 but also Reg3a, Reg3b, and Reg3g are induced, which may compensate for the loss of putative protection normally provided by Reg2 (13) . Subfamily Reg3 members are also known as pancreatitis-associated proteins, several of which (as well as Reg1) are highly induced by acute pancreatitis (29) (30) (31) (32) (33) (34) (35) (36) . Based on a previous report and on the results shown in Fig. 4(c) (top panels), Reg2 expression was also highly induced by acute pancreatitis (12) . As demonstrated using gene deficiency, endogenous Reg3b is antiapoptotic and antiinflammatory (37); administration of recombinant Reg3a and Reg4 proteins significantly prevented L-arginineinduced or caerulein-induced acute pancreatitis (38, 39) , and Reg3a (PAP II) antibody exacerbated the pancreatitic damage (40) , indicating a general protective role by various Reg proteins. It is thus reasonable to assume gene redundancy in explaining why Reg2 gene deficiency alone did not affect the severity of pancreatitis in this study. However, the same cannot be said regarding the changes caused by obesity and aging.
In WT mice, normal aging is known to result in diminished b-cell proliferation but also in an overall hypertrophic expansion as a way to compensate for decreased insulin sensitivity (4). In Reg2 2/2 mice, decreased b-cell hypertrophy and overall b-cell ratio were observed, indicating that the normal production of Reg2 promotes b-cell growth (at least in size) in aged mice and that the effect cannot be compensated by other Reg members. Indeed, although both Reg1 and Reg2 are presumed to play important roles in aging, only Reg2 level was maintained; Reg1 expression was significantly decreased in 30-vs 3-month-old mice (6) . Further, to decrease b-cell hypertrophy, a decreased cell proliferation could have occurred somewhere between 3 to 13 months, which was not measured; the lack of Ki67 labeling in the aged mice was inconclusive. In future studies, it would be interesting to treat aged Reg2 2/2 mice with recombinant Reg2 protein to directly rescue b-cell hypotrophy and/or hypoplasia. The decrease in b-cell mass may at least in part lead to decreased insulin production, which, together with increased adiposity, adipose inflammation, and hepatic steatosis, causes glucose intolerance. On the other hand, there was a slight increase or at least no sign of decrease in insulin sensitivity; glucose intolerance was unlikely to be caused by impaired insulin sensitivity. A decreased insulin level would relieve the inhibition on lipolysis and cause an increased release of fatty acids to further feed hepatic steatosis. Whether Reg2 gene deficiency causes the changes in adipose tissue and the liver directly or secondary to the islet change is unclear, although Reg2 is not known to be expressed in those two tissues (7).
In HFD-induced obesity, the WT mice were able to compensate significantly in b-cell proliferation and hypertrophy and serum insulin level. These are the normal responses to the obesity-induced insulin resistance that can delay the onset of glucose intolerance. In Reg2 2/2 mice after HFD, we detected diminished b-cell hypertrophy and proliferation. These changes may contribute to an overall decrease of the b-cell ratio to one-third of that of the WT level and may cause a decrease in serum insulin level (Fig.  5) . Because only the level of Reg2, but not other Reg members, was significantly elevated after HFD [also confirmed in Fig. 4(c) , middle panels], a total deletion is expected to have a significant effect (10) . Although more direct evidence is required using in vitro cultured primary islets and in vivo rescue of Reg2 gene deficiency, our results seem to indicate that normal production of Reg2 is essential for promoting b-cell expansion in response to HFD and obesity. An alternative explanation would be that a possible increase in insulin sensitivity caused by Reg2 deficiency in the face of HFD-induced obesity results in reduced hyperglycemia and in a drive for b-cell expansion.
We have yet to carefully analyze insulin sensitivity using a hyperinsulinemic, euglycemic clamp, and Reg2 is not known to be expressed in major insulin target tissues such as skeletal muscle, adipose tissue, and liver. The only controversy in our view is the partial prevention of hyperglycemia in HFD-fed Reg2 2/2 mice. Because a diminished or a lack of compensation in b-cell mass and insulin production in gene-deficient mice is expected to worsen T2D vs WT littermates, the opposite was observed [ Fig. 4(b) ]. Nevertheless, this result seems consistent with the model used by Mehran et al. (41) , which was developed through combinational deletions of the two insulin genes. They propose that HFD causes hyperinsulinemia first, which promotes obesity and insulin resistance. Based on that model, our Reg2 2/2 mice with demonstrated decreases in b-cell ratio and insulin level would have prevented obesity, but we detected the same degree of weight gain and obesity from WT [ Fig. 4(a) ]. Furthermore, Reg2 deficiency would have resulted in improved insulin sensitivity and glucose tolerance. We found a higher level of insulin sensitivity index but no change in glucose tolerance. Although we found decreased islet ratio and insulin levels in both aged and HFD-fed Reg2 2/2 mice, the glucose tolerance in the mice showed a trend of opposite changes (i.e., aged Reg2 2/2 mice were impaired, whereas young ones after HFD had unchanged glucose tolerance vs WT-HFD). Glucose tolerance is determined by a dynamic interplay of the levels of insulin release and insulin sensitivity.
As recently reported, hyperinsulinemia may cause obesity and insulin resistance (41, 42) . In our study, WT mice after HFD showed hyperinsulinemia and hyperglycemia. However, the insulin level in Reg2 2/2 mice fed HFD was not significantly increased compared with that of WTchow; blood glucose level was significantly diminished from WT-HFD at most time points. This is consistent with the notion that limited compensation in insulin secretion improves insulin sensitivity and limits the development of insulin resistance and hyperglycemia. We suspect that in young mice fed HFD, improved insulin sensitivity compensates for the lack of insulin production, resulting in unchanged glucose tolerance. However, after 13 to 14 months of exposure to Reg2 deficiency, decreased b-cell growth may dominate over improved insulin sensitivity, thereby impairing the animals' ability to dispose of glucose effectively (Fig. 6 ). If that is true, T2D pathophysiology may be managed better; for example, we should prevent overcompensating islet expansion and insulin production at prediabetic stages to delay the onset of glucose intolerance and T2D. Based on the evidence presented here, normal expression of the Reg2 gene seems to be required for islet expansion in response to HFD and aging. Reg2 gene deficiency maintained glucose tolerance in HFD-fed young mice but caused its impairment in aged mice. This may be explained by an interplay between decreased insulin level and increased insulin sensitivity. Although Reg2 expression does not seem to be required for maintaining islet function and glucose homeostasis under normal conditions, pancreatic islet compensation in response to aging and HFD-induced obesity seems to depend on it.
